Oral IMR-687 Seen to Lessen VOCs, Pain Crises in Patients in Phase 2a Trial

Oral IMR-687 Seen to Lessen VOCs, Pain Crises in Patients in Phase 2a Trial

282662

Oral IMR-687 Seen to Lessen VOCs, Pain Crises in Patients in Phase 2a Trial

Six months of treatment with oral IMR-687 safely and effectively reduced the number of vaso-occlusive crises (VOCs) and other disease-associated pain crises in adults with sickle cell disease (SCD), updated data from a Phase 2a clinical trial show. Most benefits were observed when patients were given the highest doses, its researchers noted, and combining the therapy with hydroxyurea did not appear to provide additional benefits. “I am encouraged by the incremental data from this readout, especially…

You must be logged in to read/download the full post.